

Title: Mathematical modeling of the waning of anti-RBD IgG SARS-CoV-2 antibody titers after a two-dose BNT162b2 mRNA vaccination.

Authors: Javier Torres¹⁺, Jesús Ontañón²⁺, Carlos de Cabo^{3#}, Julia Lozano⁴, María Ángeles Requena⁵, Joaquín Blas⁴, José Luis Rodríguez-García⁵, Antonio Mas⁶, Francisco J. Cimas^{7#}, Javier Solera^{5,8*}

+ first authorship

* senior authorship

corresponding authors

1 Clinical Analysis Department, Albacete General Hospital c/ Hermanos Falcó 37, E-02008 Albacete, Spain.

2 Immunology Unit, Albacete General Hospital, c/ Hermanos Falcó 37, E-02008 Albacete, Spain.

3 Research Department, Albacete General Hospital, c/ Hermanos Falcó 37, E-02008 Albacete, Spain. Electronic address: carlostd@sescam.jccm.es.

4 Microbiology Department, Albacete General Hospital, c/ Hermanos Falcó 37, E-02008 Albacete, Spain.

5 Internal Medicine Department, Albacete General Hospital, c/ Hermanos Falcó 37, E-02008 Albacete, Spain

6 Department of Medical Sciences. Faculty of Medicine. University of Castilla - La Mancha at Albacete.

7 Servicio de Instrumentación Biomédica. University of Castilla - La Mancha at Albacete. Electronic address: franciscojose.cimas@uclm.es.

8 Internal Medicine Department, University of Castilla - La Mancha at Albacete, Faculty of Medicine, c/Almansa, 14, E-02008 Albacete, Spain. Electronic address: solera53@gmail.com.

Corresponding authors:

Dr. Carlos de Cabo de la Vega

Hospital General Universitario de Albacete, Unidad de Neuropsicofarmacología

Edificio de Investigación, 3ª planta, c/ Hermanos Falcó, 37

E-02008, ALBACETE, SPAIN

Email: carlostd@sescam.jccm.es

Dr. Francisco J. Cimas

Servicio de Instrumentación Biomédica

Facultad de Medicina/CRIB. Av. Almansa 14.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

02008, Albacete, Spain

Email: franciscojose.cimas@uclm.es

1 Abstract

2 Objective. Serum antibody levels have been linked to immune protection in SARS-CoV-2
3 infection. After exposure to the virus and/or vaccination there is an increase in serum antibody
4 titers followed by progressive non-linear waning of antibody levels. Our aim was to find out if
5 this waning of antibody titers would adjust to a mathematical model.

6 Methods. We studied serum anti-RBD (receptor binding domain) IgG antibody titers over a ten-
7 month period in a cohort of 54 health-care workers who were either never infected with SARS-
8 CoV-2 (naive, nHCWs group, n = 27) or previously infected (experienced, eHCWs group, n = 27)
9 with the virus after the second dose of the BNT162b2 mRNA vaccine. We have selected a risk
10 threshold of 1000 UA/ml anti-RBD Ab titer for symptomatic infection based on the upper titer
11 threshold for those volunteers who suffered infection prior to the omicron outbreak. Two
12 mathematical models, exponential and potential, were used to quantify antibody waning
13 kinetics and the relative quality of the goodness of fit to the data between both models was
14 compared using the Akaike Information Criterion.

15 Results. We found that the waning of anti-RBD IgG antibody levels adjusted significantly to both
16 exponential and potential models in all participants from both the naïve and experienced
17 groups. Moreover, the waning slopes were significantly more pronounced for the naive when
18 compared to the experienced health-care workers. In the nHCWs group, titers would descend
19 below this 1000-units threshold at a median of 210.6 days (IQ range: 74,2). However, for the
20 eHCWs group, the risk threshold would be reached at 440.0 days (IQ range: 135,2) post-
21 vaccination.

22 Conclusions. The goodness of the fit of the anti-RBD IgG antibody waning would allow us to
23 predict when the antibody titers would fall below an established threshold in both naive and
24 previously infected subjects.

25

26

27

28

29

30

31

32

33

34 Introduction

35 COVID-19 pandemic has represented a huge challenge for societies and health systems all over
36 the world. While there are more and more people with an immune shield, either because they
37 had recovered from primary SARS-CoV-2 infection, they have been vaccinated or both (1), the
38 virus has continued to evolve with the emergence of new genetically distinct variants that imply
39 a higher transmission rate and a decrease in the immune protection against re-infection (2-4)

40 Vaccines against SARS-CoV-2 have demonstrated a high degree of protection against Covid19
41 over time, at least in terms of severe disease and mortality (5,6). However, immunity to SARS-
42 CoV-2 declines in a nonlinear fashion (7,8) and makes it difficult to estimate risk and take
43 decisions about when to schedule booster vaccines (9). In fact, it has already been described
44 that antibody (Ab) titers correlate with immune protection, and it has been used to predict
45 protection against infection (10-14). This decrease in protection is different in vaccinated
46 subjects without previous infection (naïve) and previously-infected (experienced) vaccinated
47 subjects due to hybrid immunity (1,15-16). In this work, we analyzed the anti-RBD IgG Ab titer
48 and the breakthrough infections from February 2021 to December 2021, just before the third
49 vaccination dose, in a cohort of HealthCare Workers (HCW) vaccinated with RNA BNT162b2
50 (Pfizer Biotech.) vaccine in January 2021. We propose that it is possible to model the waning in
51 the level of anti-RBD Ab titer over time through simple mathematical models. We have used the
52 exponential and potential models, which are accurate models to analyze the non-linear waning
53 of antibody titers for both natural infection and vaccination (11, 17-20). Our aim is to develop a
54 simple way to describe the evolution of the antibody titer over time. This would allow us to
55 predict a personalized optimal moment of administration of the booster vaccine dose as well as
56 estimate the risk of infection and its severity according to an established threshold (correlate of
57 protection).

58

59 Methods

60 **Study design and oversight:** We conducted an observational prospective longitudinal study
61 continuing from a previously reported HCWs cohort from the Albacete General Hospital (CHUA,
62 Spain) (21). This study was officially approved by the *Comité de Ética de la Investigación con*
63 *medicamentos (CEIm) de la Gerencia de Atención Integrada de Albacete* (Internal code: 2021-12
64 EOm). Written informed consent was obtained from all study participants. These HCWs were
65 vaccinated in January 2021 with the BNT162b2 mRNA vaccine. In brief, 63 HCWs from the
66 original CHUA cohort volunteered to measure their antibody levels at several time-points during
67 three periods. First, before the onset of vaccination; second, 7, 14 and 21 days after each of the
68 two doses and third, monthly up to the administration of the third dose of the vaccine
69 (December 2021). Of the 63 original HCW, we selected 54 subjects that complied with the
70 follow-up schedule; at least 4 decreasing consecutive measurements after completing the
71 vaccination schedule. Subjects were classified into two groups: naïve health-care workers
72 (nHCW), which included participants without clinical or laboratory data suggestive of infection
73 with the SARS-CoV-2 virus prior to vaccination, and experienced health-care workers (eHCW),
74 consisting of those with previous SARS-CoV-2 infection. The kinetics of antibody decay was

75 evaluated individually. For each subject, the point of maximum antibody level (between 7 and
76 45 days after second dose vaccination) and all those corresponding to the determinations made
77 during the following 10 months were taken. We monitored the eventual appearance of
78 breakthrough symptomatic or asymptomatic infections. Breakthrough infections were defined
79 as the detection of SARS-CoV-2 by PCR 14 or more days after receiving the second dose.

80 **Biochemical analysis:** Total IgG antibody levels against the S1 subunit of the SARS-CoV-2 virus
81 spike protein that binds to the receptor binding domain (RBD) were measured using the SARS-
82 CoV-2 IgG II Quant immunoassay in the ARCHITECT i-System (Abbott, Abbott Park, US). The
83 analytical measurement range is from 21 to 80,000 AU/mL and we used the manufacturer's
84 recommended cutoff point of 50 AU/mL for determining positivity. To convert AU/ml into
85 international standard WHO units the conversion factor is 1/7 (22). To assess re-infection
86 detection, PCR was performed in samples of nasopharyngeal exudates that were collected in
87 tubes with 3 ml of universal transport medium (UTM) without inactivation and routinely sent to
88 our laboratory for diagnosis of SARS-CoV-2. Samples were extracted with MagMax™
89 Viral/Pathogen Nucleic Acid Isolation Kit (ThermoFisher) reagents using the KingFisher extractor
90 (ThermoFisher) following manufacturer instructions. For the qualitative detection of SARS-CoV-
91 2 nucleic acid, the commercial TaqPath™ COVID-19 CE-IVD Kit was used together with the
92 ThermoFisher QuantStudio 5 (QS5) thermal cyclor.

93 **Statistical analysis:** Quantitative demographic variables were expressed as mean and range,
94 mean and standard deviation (SD) and confidence interval 95% (CI). Qualitative variables were
95 expressed as number and percentage. Total anti-SARS-CoV-2 spike RBD region IgG antibody
96 levels were reported using geometric mean concentrations (GMC).

97 Normality of the distributions were tested using Lilliefors test and variances between
98 populations using the F-test. The two-tailed U-Mann-Whitney non-parametric method was used
99 to compare different means between the nHCW and eHCW groups. Within-group differences in
100 total IgG levels obtained at the different time points were assessed using the two-tailed
101 Wilcoxon Sign test. Chi-square and Fisher's test were used to compare categorical data. All the
102 confidence intervals, as well as the statistical tests, were calculated with a significance level of
103 95%.

104 Two mathematical models were used to quantify antibody waning kinetics. First, the exponential
105 model $y = A \cdot e^{t \cdot x}$ was used for each patient, where y is the SARS-CoV-2 RBD IgG antibody
106 concentration, A is the exponential transformation of the extrapolated SARS-CoV-2 IgG
107 concentration of the HCW at day 0, t is the slope of the model and x is the time after vaccination
108 in days. The parameters of the model were estimated by fitting a linear model to the Naepierian
109 logarithm of the SARS-CoV-2 RBD IgG concentration versus the time after vaccination expressed
110 in days, using the Ordinary Least Squares method. The exponential curve is afterwards obtained
111 by reversing the logarithmic transformation.

$$\begin{aligned} (\text{RBD IgG} - \text{SARS} - \text{CoV} - 2) &= A \cdot e^{t \cdot (\text{time in days})} \\ \text{Ln}(\text{RBD IgG} - \text{SARS} - \text{CoV} - 2) &= \text{Ln}(A) + t \cdot (\text{time in days}) \end{aligned}$$

112

113 **Equation 1: Exponential and linear representations of the concentration of IgG versus time.**

114 A potential model was also used, represented by the curve $y = A \cdot x^t$ employing the same
115 variable definitions as before. The adjustment was performed by Ordinary Least Squares
116 regression of the Napierian logarithm of the concentration of SARS-CoV-2 IgG versus the
117 Napierian logarithm of time. Exponential transformation was performed to obtain the curve
118 from the linear adjustment:

$$\begin{aligned} \ln(\text{RBD IgG-SARS-CoV-2}) &= A + t \cdot \ln(\text{time in days}) \\ \text{RBD IgG-SARS-CoV-2} &= e^A (\text{time in days})^t \end{aligned}$$

119

120 **Equation 2: Potential and linear representations of the concentration of IgG versus time.**

121 Relative quality of the goodness of fit to the data between both models was compared using the
122 Akaike Information Criterion (AIC) (23). AIC was calculated for each patient and model. The
123 difference of the AIC value was calculated as the exponential model's AIC minus the potential
124 model's AIC. Positive delta values were interpreted as a better exponential fit and negative
125 values as a better potential fit.

126 An ideal waning curve was built for each mathematical model and sub-cohort using the
127 corresponding mean values for each group.

128 The calculations were carried out with the statistical software R, version 4.0.2 and data
129 visualization figures were drawn with the ggplot2 package.

130 Results

131 1- Characteristics of the Study Population

132 54 HCWs were included in the study, of which 27 were nHCW and 27 eHCW regarding previous
133 infections with SARS-CoV-2 before vaccination. The epidemiological characteristics of the
134 participants are described in Table 1. No significative differences were found regarding age, sex,
135 number of Ab-titer determinations (timepoints) and follow-up duration between the two
136 groups.

	nHCW	eHCW	p-value
Number	27	27	
Age in years. Mean ± SD (Range)	42.04±14.91 (25-62)	47.96±12.78 (25-67)	0,12 *
Number of females (%)	19 (70%)	19 (70%)	1.00 **
Follow-up days after the second dose of the vaccine. Mean ± SD (Range)	293.52 ± 3.50 (21-27)	293.07 ± 10.82 (21-28)	0.84 *
Number of determinations per subject. Mean ± SD (Range)	6.85 ± 2.35 (4-12)	6.33 ± 1.33 (4-10)	0.32 *

137

138 **Table 1. Demographic characteristics of the participants in the study:***U-Mann-Whitney test;
139 ** Chi Square test

140


141 **2-A differential decrease in Ab titers after the vaccine was observed between nHCWs and**
142 **eHCWs**

143 The geometric mean of the maximal post-vaccine values for the eHCW group was two times
144 higher than the nHCW group (46.682 AU/ml Vs 23.623 AU/ml, p-value < 0.001).

145 We plotted the individual Ab waning curves from the measured Ab titers for each HCW using
146 both exponential and potential models (Supp. 1). We observed a decrease in the anti-RBD Ab
147 titers from the maximum post-vaccine values over the following 10 months in both the naïve
148 and eHCW groups (Fig. 1A and 1B). The slopes of the curves for the nHCWs were more
149 pronounced when compared with the eHCWs in both the exponential and potential models.

150 First, for each HCW the individual data were fitted to an exponential curve, applying a linear
151 regression method. Within the nHCWs group, the decay rate t had a median value of -0.015736
152 (Interquartile range: -0.019122 to -0.012970) and a mean value of -0.016137 (SD: 0.00412; 95%
153 CI: -0.017692 to -0.014582). The R^2 values for all the adjustments were between 0.899 and
154 0.996, with an average of 0.957 which demonstrates a good fit of the curve for every individual
155 to their experimental data. All the p-values for the adjustments were significant (p-value range:
156 9.18E-7 to 5.0E-3) (Fig. 1A).

157 For the eHCWs group, the median t parameter was -0.008496 (Interquartile range: -0.009983 to
158 -0.007256) and the mean value was -0,009054 (SD: 0,00299; 95% CI: -0.01018 to -0.0079). Their
159 calculated curves had a good fit to the experimental data similar to the one found for the nHCW
160 group (Fig. 1A). The R^2 value for the adjustments was between 0.907 and 0.998, with an average
161 value of 0.954. All the corresponding p-values were significant (p-value range: 1.406E-7 to
162 0.844E-3).



163


164 **Fig. 1. Time-course of anti-RBD IgG antibody titers for each individual HCW and the mean**
165 **curves for exponential (A) and potential (B) models.** Individual timepoints for each HCW are
166 represented as open circles (red, eHCWs and blue, nHCWs). Each continuous line represents an

167 individual antibody waning ideal curve for individual HCWs; dashed lines represent the ideal
168 mean curves. The horizontal dashed line indicates 1.000 AU/ml.

169 Second, in the case of the potential adjustment, for the nHCWs group, the parameter t
170 corresponding to the linear regression slope when representing the \ln of the SARS-Cov-2 IgG
171 concentration against the \ln of the time had a median value of -1.598 (Interquartile range: -
172 1.803 to -1.403) and a mean value of -1.623 (SD: 0.240; 95% CI: -1.713 to -1.523). A good fit of
173 the curve to the experimental data was found for each individual (Fig. 1B). The R^2 values for all
174 the adjustments were between 0.970 and 0.999, with an average of 0.991. All the p-values for
175 the adjustments were significant (p-value range: 1.31E-9 and 2.27E-3).

176 Regarding the eHCWs group, analysis showed a median parameter t of -0.977 (Interquartile
177 range: from -1.161 to -0.877) and a mean value of -1.005 (SD: 0.247; 95% CI: -1.098 to -0.912).
178 The calculated curves had a similarly good adjustment to the experimental data found for the
179 nHCWs group (Fig. 1B). The R^2 value for the adjustments was found to be between 0.931 and
180 0.9997, with an average value of 0.988. All the corresponding p-values were significant (p-value
181 range: 4.91E-12 and 7.91E-3).

182 The slopes of the ideal curves for the nHCWs were more pronounced when compared with the
183 eHCWs in the exponential (1.801E-9) and potential models (p-value: 9.399E-13), with a stronger
184 significance in the last one (Fig. 2).



185

186 **Fig. 2. Notched box and whisker comparison of the mean of the ideal curves slope for**
187 **exponential (A) and potential (B) models.** Box width is proportional to the number of
188 observations in each group (red, eHCWs and blue, nHCWs).

189

190 Comparison of both models was calculated for each individual HCW using the value of the AIC
191 difference for the exponential minus potential model (ΔAIC) (Supp. 3). This difference was
192 positive for 46/54 HCW (85.2%), denoting a better fit for the potential model. There were no
193 statistically significant differences between the nHCWs and eHCWs according to the Fisher test
194 (p-value: 0.704), denoting a better fit for the exponential model in both groups (Supp. Table 3).

195 **3- Characterization of breakthrough infections in the studied cohort.**

196 Of the 54 HCWs included in this study, only 4 (7,4%) had breakthrough infections (Table 2).
197 Although more of them (3) belonged to the nHCWs group and just 1 to the eHCWs group, no
198 statistically significant differences were found (p -value = 0.6104). Two of nHCWs were infected
199 in July 2021, when the predominant SARS-CoV-2 variant was delta and the other two infections
200 happened in December 2021 when the predominant variant was Omicron. We estimated the
201 anti-RBD antibody levels at the time of infection for all four HCWs. For the nHCWs the estimated
202 value was < 1000 AU/ml, with a mean value of 504.2 AU/ml and a maximum of 932.6 AU/ml and
203 a minimum of 15.0 AU/ml. For the eHCW, the anti-RBD antibody levels at the time of infection
204 were < 4000 AU/ml (Table 2). The curve fitting R^2 value for that subject was 0.955.

Subject	Group	Sex	Previous diagnosis	2nd dose date	Break. inf. date	Titer on break inf.	R^2
54	N	F	X	02/2021	07/2021	563.9/1265.9	0.9715/0.9866
55	N	M	X	02/2021	07/2021	932.6/2276.6	0.9743/0.9764
48	N	F	X	02/2021	11/2021	16.0/527.8	0.9734/0.9956
26	P	F	03/2020	02/2021	12/2021	2960.5/4029.5	0.955/0.9769

205 **Table 2. Parameters of interest of the breakthrough infection cases detected during our study.**
206 Parameters include group, sex, existence of previous diagnosis, 2nd dose date, breakthrough
207 infection date (in month/year format), anti-RBD IgG titer in breakthrough infection and adjusted
208 R^2 (calculated by exponential model/calculated by potential model).

209 **4- Usefulness of the model to predict Abs levels and use of the data obtained in decision**
210 **making**

211 The post-vaccination half-life of the RBD-Ab titers estimated by the exponential model was 45.84
212 days on average (SD: 12.09, 95% CI: 41.28-50.41) for the nHCW group and, whereas for the
213 eHCWs group, the half-life was 85.67 days (SD: 34.95; 95% CI: 72.48 to 98.85 days). This result
214 for eHCWs is 1.87-fold higher than in the nHCWs group.

215 We established a preliminary risk threshold of 1000 UA/ml anti-RBD Ab titer for symptomatic
216 infection based on the upper titer threshold for those volunteers who suffered infection prior
217 to the omicron outbreak. In the nHCWs group, titers would descend this 1000-units threshold

218 at 221.1 days post-vaccination, on average (SD: 53.1 days). The median for this group was 210.6
219 days (Interquartile range: 74,2). However, for the eHCWs group, the risk threshold would be
220 reached at 483.3/38880 days post-vaccination, on average (SD: 229.1 days). For this group, the
221 median is located at 440.0 days (Interquartile range: 135,2). The difference in the predicted
222 mean time to descend to the risk threshold between nHCWs and eHCWs was statistically
223 significant (p-value = 2.14E-12, Mann-Whitney U-test). Interestingly, in one individual from the
224 eHCWs group a value below the 1000 UA/ml risk threshold would be reached as late as 1.468,9
225 days. Predictions made with the potential model develop an asymptotic behavior at long periods
226 and are reflected on Supp. Table 2.

227 According to the extrapolations made, when 95% of the nHCWs group would have already fallen
228 below this limit, only 5 (18.5 %) of the eHCWs would have fallen below this value, while the
229 remaining 22 (81.5 %) would be still above. Similarly, when 50% of the eHCWs patients would
230 be below the threshold, all the nHCW patients would already be below it.

231

232 Discussion

233 In this study, we modeled the observed waning in anti-RBD IgG Ab levels in a cohort of HCWs
234 following a second dose of BNT162b2 vaccine during 10 months by using two different
235 mathematical approximations, the exponential and potential models. Both models adjust well,
236 with strong correlation coefficients and statistical significance (Supp. Fig. 1). Thanks to the
237 goodness of adjustment of the curves to either potential or exponential models, we would be
238 able to predict individual Ab titers after the second those of the mRNA BNT162b2 vaccination
239 over time by counting on just two Ab determination timepoints.

240 Interestingly, the potential model offers a better fitting for the early timepoints of
241 determination, consistent with the quick waning in Ab titers during the first weeks after the peak
242 levels. This observation is consistent with previous reports which describe a rapid decline in
243 SARS-CoV-2 IgG Ab titer during the first four months after antigen contact, followed by a gentler
244 waning over the following 7 months (11-12, 24). At this point, Ab levels correlate with the
245 presence of antigen-specific plasma cells found in bone marrow (25). The potential model also
246 presents a better adjustment than the exponential model according to the AIC criterion. A
247 negative delta value was found for 85% of the subjects (Supp. Table 1). The exponential and
248 potential models have been previously compared to describe anti-RBD IgG titer waning in a
249 smaller, naïve cohort (11). That same study found a more robust fitting of the potential model
250 for the anti-RBD Ab waning curve, similarly to our results. However, they found a better
251 adjustment of the exponential model for other determinations of neutralizing Ab.

252 The nHCWs and eHCWs sub-cohorts have statistically significant different slopes, showing a
253 pronounced decline for nHCWs in both models. Multiple studies have described that vaccinated
254 subjects with previous infection have stronger and longer lasting response to vaccines than naïve
255 ones, as well as lower risk of infection (1,6,15-16), which is attributed to hybrid immunity. Our
256 results therefore agree with the proposed lower risk of infection for hybrid immunity bearers.
257 Compared to previous works, our study provides a detailed Ab titer evolution throughout more

258 timepoints and also demonstrates significant differences between the nHCWs and eHCW sub-
259 cohorts slopes.

260 We found four subjects that had breakthrough infections detected during the follow-up of our
261 cohort. All of them were mild and did not require hospitalization. Three of them corresponded
262 to nHCWs and only 1 to eHCWs. The number of infections is higher for nHCWs as it has been
263 widely described (1, 15-16). However, no statistical significance was found due to the reduced
264 number of relapse cases given the small size of the cohort. With that in mind, those HCWs who
265 experienced relapses had lower Ab levels at the time of infection. Conversely, the average Ab
266 level of those who did not relapse was higher than those who did. The level of Abs against SARS-
267 CoV-2 can be a marker of protection or risk (a correlate of protection) to determine individual
268 risk of infection and optimal moment for vaccine booster. In this regard, testing our model in
269 larger cohorts with more breakthrough infections will allow us to estimate more accurate risk of
270 infection thresholds and correlates of protection.

271 Notwithstanding the above-mentioned goodness of fit of the models, we observed a high
272 individual variability among the curves, that was more pronounced in nHCWs (Fig. 1) It is
273 remarkable how, within the two well-differenced groups in terms of presence or absence of
274 hybrid immunity, there is such a high heterogeneity in their anti-RBD Ab titer curves. This
275 variability included subjects with a sustained low level in antibody titers (vulnerable to infection)
276 while others were able to maintain high antibody titers over time, which would confer
277 protection against infection. In particular, we found that one eHCW that presented such high
278 sustained Ab titers that would not need a booster vaccination. These two types of populations
279 of individuals according to their Ab response to vaccination have been well characterized by
280 Nakamura et al. (24) in a larger cohort. The variability in the anti-RBD IgG antibody response
281 supports the use of individual curves versus using a mean curve to attempt to predict Ab titers
282 over time.

283 **Limitations**

284 Our study was conducted in a small, homogeneous cohort of HCWs, who were mostly middle-
285 aged and healthy subjects and therefore it may not represent the general population. Moreover,
286 due to the period in which the study was performed, no new SARS-CoV-2 variants nor other
287 vaccines or dose patterns were considered. Our model needs rigorous evaluation using data
288 from different cohorts. Besides, antibody level estimations with our model for dates outside our
289 period of study should be taken with caution. This model, like many other predictive models, is
290 based on multiple regression techniques. In a recent study, this approach was combined with
291 machine learning (19), which we did not use in our work. Nonetheless, in our study we do
292 describe detailed individual waning curves comparing eHCWs with nHCWs at several timepoints
293 and for a similarly long follow-up period (ten months).

294

295 **Conclusion**

296 We described both exponential and potential models as parsimonious models that allow
297 determination of the anti-RBD IgG Ab titer, building a personalized waning curve with only two

298 antibody titer determinations. Therefore, we can estimate the moment when antibody titers
299 drop below a certain threshold. Nevertheless, it should be noted that predictions would be most
300 reliable within the observation period used in this work (10 months after the second dose of the
301 vaccine). Regardless of the model used, eHCWs have a lower waning slope and longer
302 persistence of antibody titers than nHCWs. Consequently, different vaccination booster
303 schedules should be advised according to the individual persistence of antibody levels. Both the
304 exponential and potential versatile models allow the application of different thresholds that
305 mark variables of clinical interest such as risk of hospitalization or symptomatic infection. Our
306 modelization could also be used under different conditions which may alter conferred
307 protection, such as new vaccines or viral variants. Our approach provides a tool for personalized
308 predictions of Ab levels, and, thus, the rationalization of the administration of booster doses of
309 anti-SARS-CoV-2 vaccines, applying them only when necessary and avoiding potential side-
310 effects.

311

312 **Role of funding source**

313 This work received the financial support of the *Pruebas de diagnóstico COVID19 200095MEZ*
314 Project from Universidad de Castilla-La Mancha, which had no further role in study design, the
315 collection, analysis and interpretation of the data, in the writing of the report or in the decision
316 to submit the paper for publication.

317

318 **References**

- 319 1. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, Alroy-Preis S,
320 Huppert A, Milo R. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-
321 2. N Engl J Med. 2022 Jun 9;386(23):2201-2212. doi: 10.1056/NEJMoa2118946.
- 322 2. Hachmann NP, Miller J, Collier AY, Ventura JD, Yu J, Rowe M, Bondzie EA, Powers O,
323 Surve N, Hall K, Barouch DH. Neutralization Escape by SARS-CoV-2 Omicron Subvariants
324 BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022 Jul 7;387(1):86-88. doi:
325 10.1056/NEJMc2206576.
- 326 3. Marking U, Havervall S, Greilert Norin N, Christ W, Gordon M, Ng H, Blom K, Phillipson
327 M, Mangsbo S, Smed Sörensen A, Nilsson P, Hober S, Åberg M, Klingström J, Thålin
328 C. High rate of BA.1, BA.1.1 and BA.2 infection in triple vaccinated. medRxiv preprint doi:
329 10.1101/2022.04.02.22273333; April 3, 2022.
- 330 4. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, Anyaneji UJ, Bester
331 PA, Boni MF, Chand M, Choga WT, Colquhoun R, Davids M, Deforche K, Doolabh D, du
332 Plessis L, Engelbrecht S, Everatt J, Giandhari J, Giovanetti M, Hardie D, Hill V, Hsiao NY,
333 Iranzadeh A, Ismail A, Joseph C, Joseph R, Koopile L, Kosakovsky Pond SL, Kraemer MUG,
334 Kuate-Lere L, Laguda-Akingba O, Lesetedi-Mafoko O, Lessells RJ, Lockman S, Lucaci AG,
335 Maharaj A, Mahlangu B, Maponga T, Mahlkwane K, Makatini Z, Marais G, Maruapula
336 D, Masupu K, Matshaba M, Mayaphi S, Mbhele N, Mbulawa MB, Mendes A, Mlisana K,
337 Mnguni A, Mohale T, Moir M, Moruisi K, Mosepele M, Motsatsi G, Motswaledi MS,

- 338 Mphoyakgosi T, Msomi N, Mwangi PN, Naidoo Y, Ntuli N, Nyaga M, Olubayo L, Pillay S,
339 Radibe B, Ramphal Y, Ramphal U, San JE, Scott L, Shapiro R, Singh L, Smith-Lawrence P,
340 Stevens W, Strydom A, Subramoney K, Tebeila N, Tshiabuila D, Tsui J, van Wyk S, Weaver
341 S, Wibmer CK, Wilkinson E, Wolter N, Zarebski AE, Zuze B, Goedhals D, Preiser W,
342 Treurnicht F, Venter M, Williamson C, Pybus OG, Bhiman J, Glass A, Martin DP, Rambaut
343 A, Gaseitsiwe S, von Gottberg A, de Oliveira T. Rapid epidemic expansion of the SARS-
344 CoV-2 Omicron variant in southern Africa. *Nature*. 2022 Mar;603(7902):679-686. doi:
345 10.1038/s41586-022-04411-y.
- 346 5. Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, Ramsay M, Lopez Bernal
347 J. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms,
348 hospitalization and death in England. *Nat Med*. 2022 Apr;28(4):831-837. doi:
349 10.1038/s41591-022-01699-1.
- 350 6. Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19
351 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total
352 population cohort study in Sweden. *Lancet Infect Dis*. 2022 Jun;22(6):781-790. doi:
353 10.1016/S1473-3099(22)00143-8.
- 354 7. Szanyi J, Wilson T, Scott N, Blakely T. A log-odds system for waning and boosting of
355 COVID-19 vaccine effectiveness. *Vaccine*. 2022 Jun 21;40(28):3821-3824. doi:
356 10.1016/j.vaccine.2022.05.039.
- 357 8. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, Doolman R, Asraf K,
358 Mendelson E, Ziv A, Rubin C, Freedman L, Kreiss Y, Regev-Yochay G. Waning Immune
359 Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *N Engl J Med*. 2021
360 Dec 9;385(24):e84. doi: 10.1056/NEJMoa2114583.
- 361 9. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch
362 I, Humphries HE, Jepson B, Kelly EJ, Plested E, Shoemaker K, Thomas KM, Vekemans J,
363 Villafana TL, Lambe T, Pollard AJ, Voysey M; Oxford COVID Vaccine Trial Group.
364 Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
365 *Nat Med*. 2021 Nov;27(11):2032-2040. doi: 10.1038/s41591-021-01540-1.
- 366 10. Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Kent SJ, Triccas JA,
367 Khoury DS, Davenport MP. Neutralising antibody titres as predictors of protection
368 against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *Lancet*
369 *Microbe*. 2022 Jan;3(1):e52-e61. doi: 10.1016/S2666-5247(21)00267-6.
- 370 11. Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B,
371 Ledgerwood JE, Mascola JR, Graham BS, Lin BC, O'Dell S, Schmidt SD, Widge AT, Edara
372 VV, Anderson EJ, Lai L, Floyd K, Roupheal NG, Zarnitsyna V, Roberts PC, Makhene M,
373 Buchanan W, Luke CJ, Beigel JH, Jackson LA, Neuzil KM, Bennett H, Leav B, Albert J,
374 Kunwar P; mRNA-1273 Study Group. Antibody Persistence through 6 Months after the
375 Second Dose of mRNA-1273 Vaccine for Covid-19. *N Engl J Med*. 2021 Jun
376 10;384(23):2259-2261. doi: 10.1056/NEJMc2103916.
- 377 12. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ,
378 Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune
379 protection from symptomatic SARS-CoV-2 infection. *Nat Med*. 2021 Jul;27(7):1205-
380 1211. doi: 10.1038/s41591-021-01377-8.
- 381 13. Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, Sajadi
382 MM. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health

- 383 Care Workers Previously Infected With SARS-CoV-2. *JAMA*. 2021 Apr 13;325(14):1467-
384 1469.
- 385 14. Zurac S, Vladan C, Dinca O, Constantin C, Neagu M. Immunogenicity evaluation after
386 BNT162b2 booster vaccination in healthcare workers. *Sci Rep*. 2022 Jul 26;12(1):12716.
387 doi: 10.1038/s41598-022-16759-2.
- 388 15. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, Wellington E, Khawam J, Munro K,
389 Cole M, Tranquillini C, Taylor-Kerr A, Hettiarachchi N, Calbraith D, Sajedi N, Milligan I,
390 Themistocleous Y, Corrigan D, Cromeey L, Price L, Stewart S, de Lacy E, Norman C, Linley
391 E, Otter AD, Semper A, Hewson J, D'Arcangelo S, Chand M, Brown CS, Brooks T, Islam J,
392 Charlett A, Hopkins S; SIREN Study Group. Protection against SARS-CoV-2 after Covid-19
393 Vaccination and Previous Infection. *N Engl J Med*. 2022 Mar 31;386(13):1207-1220. doi:
394 10.1056/NEJMoa2118691.
- 395 16. Hammerman A, Sergienko R, Friger M, Beckenstein T, Peretz A, Netzer D, Yaron S, Arbel
396 R. Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. *N Engl J Med*.
397 2022 Mar 31;386(13):1221-1229. doi: 10.1056/NEJMoa2119497.
- 398 17. David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P. Long-
399 term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the
400 AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
401 *Gynecol Oncol*. 2009 Dec;115(3 Suppl):S1-6. doi: 10.1016/j.ygyno.2009.01.011.
- 402 18. Martin JC, Petrecz ML, Stek JE, Simon JK, Goveia MG, Klopfer SO. Using the power law
403 model to predict the long-term persistence and duration of detectable hepatitis A
404 antibody after receipt of hepatitis A vaccine (VAQTA™). *Vaccine*. 2021 May
405 12;39(20):2764-2771. doi: 10.1016/j.vaccine.2021.03.052.
- 406 19. Nakamura N, Park H, Kim KS, Sato Y, Jeong YD, Iwanami S, Fujita Y, Zhao T, Tani Y,
407 Nishikawa Y, Yamamoto C, Kobashi Y, Kawamura T, Sugiyama A, Nakayama A, Kaneko Y,
408 Aihara K, Iwami S, Tsubokura M. A personalized antibody score for predicting individual
409 COVID-19 vaccine-elicited antibody levels from basic demographic and health
410 information. medRxiv preprint doi: 10.1101/2022.07.05.22277283; July 6, 2022.
- 411 20. Voutouri C, Hardin CC, Naranbhai V, Mohammad R, Nikmaneshi MR, Khandekarh MJ,
412 Gainord JF, Stylianopoulos T, Munn LL, Jain RK. Mechanistic model for booster doses
413 effectiveness in healthy, cancer and immunosuppressed patients infected with SARS-
414 CoV-2. medRxiv preprint doi: <https://doi.org/10.1101/2022.06.30.22277076>; July 3,
415 2022.
- 416 21. Ontañón J, Blas J, de Cabo C, Santos C, Ruiz-Escribano E, García A, Marín L, Sáez L, Beato
417 JL, Rada R, Navarro L, Sainz de Baranda C, Solera J. Influence of past infection with SARS-
418 CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics
419 and durability of the humoral immune response. *EBioMedicine*. 2021 Nov;73:103656.
420 doi: 10.1016/j.ebiom.2021.103656.
- 421 22. Perkmann T, Perkmann-Nagele N, Koller T, et al. Anti-spike protein assays to determine
422 SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays.
423 *Microbiol Spectr* 2021; 9:e00247-21.
- 424 23. Akaike, H. (1974). A new Look at the statistical model identification. *IEEE Transactions*
425 *on Automatic Control*, 19, 716–723. 10.1109/tac.1974.1100705.
- 426 24. Nakamura N, Kobashi Y, Kwang Su Kim KS, Tani Y, Shimazu Y, Zhao T, NishikawaY, Omata
427 F, Kawashima M, Yoshida M, Abe T, Saito Y, Senoo Y, Nonaka S, Takita M, Yamamoto C,

428 Kawamura T, Sugiyama A, Nakayama A, Kaneko Y, Park H, Jeong YD, Tatematsu D, Akao
429 M, Sato Y, Iwanami S, Fujita Y, Wakui M, Aihara K, Kodama T, Shibuya K, Iwami S,
430 Tsubokura M. Stratifying elicited antibody dynamics after two doses of SARS-CoV-2
431 vaccine in a community based cohort in Fukushima, Japan. medRxiv, doi:
432 <https://doi.org/10.1101/2022.06.11.22276266>; June 14, 2022.

433 25. Turner, J.S., Kim, W., Kalaidina, E. et al. SARS-CoV-2 infection induces long-lived bone
434 marrow plasma cells in humans. Nature 595, 421–425 (2021).
435 <https://doi.org/10.1038/s41586-021-03647-4>.

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454


455

456


457


458 **Supplementary material**

A





459






461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478










481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498


C









501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521








524

525 **Supp. 1. Time-course of anti-RBD IgG antibody titers for each individual HCW.** A. Individual
 526 time-courses of naïve subjects adjusted by exponential model. B. Individual time-courses of
 527 experienced subjects adjusted by exponential model. C. Individual time-courses of naïve
 528 subjects adjusted by potential model. D. Individual time-courses of experienced subjects
 529 adjusted by potential model.

530

531

532



533

534 **Supp. 2. Linear transformation of individual curves for both nHCW (in blue) and eHCW (in red)**
 535 **groups for the exponential (A) and potential (B) models.** The horizontal dashed line indicates
 536 1.000 AU/ml.

HCW	A	t	Days to 1000UA/ml	Group	Gender	HCW	A	t	Days to 1000UA/ml	Group	Gender
1	15,8080135	-1,8914051	110,568265	N	M	4	14,0499817	-0,8634894	3910,24097	P	M
3	17,0292225	-1,9673858	171,507602	N	M	6	16,5584246	-1,5666302	473,496737	P	M
8	17,0174979	-1,770098	302,294844	N	M	7	14,7564965	-1,2917928	435,219895	P	M
10	15,3536871	-1,4032562	411,08899	N	M	14	14,1081651	-1,0602658	889,924211	P	M
12	14,8906005	-1,6059897	144,123477	N	M	17	14,3292824	-0,9135997	3372,43622	P	M
13	18,0863369	-2,1303341	190,059533	N	M	18	13,576559	-0,974817	935,50117	P	M
16	15,2578339	-1,3540155	476,706195	N	M	19	12,9576581	-0,4387987	972302,092	P	M
21	16,0830036	-1,9257383	117,276623	N	M	23	15,7673683	-1,1970861	1637,59177	P	M
24	15,7112356	-1,5881334	255,516645	N	M	27	13,4497524	-0,7507702	6085,80499	P	M
25	15,414418	-1,5981804	204,940063	N	M	29	14,3430705	-0,9490032	2527,2038	P	M
26	16,3014002	-1,6501081	296,706991	N	M	30	15,0919051	-1,0928098	1788,42247	P	M
28	16,8881137	-1,87059	207,55714	N	M	31	13,139688	-0,9506635	702,995537	P	H
34	14,0468665	-1,357786	192,078888	N	H	32	14,9627976	-1,1560796	1061,61854	P	M
40	14,6307325	-1,3156361	354,301009	N	H	33	13,041826	-0,8877367	1002,03287	P	M
42	15,5782464	-1,6452166	194,439576	N	M	35	13,9070383	-0,8529091	3664,19857	P	H
43	14,229184	-1,3865755	196,413779	N	H	36	12,5941723	-0,5788456	18466,6204	P	M
44	15,85284	-1,5768801	290,803382	N	M	37	14,8709026	-1,3462621	370,556201	P	M
47	16,2525501	-1,7977297	180,929782	N	H	38	14,7826023	-1,1655583	859,445564	P	M
50	17,8463088	-2,012731	229,220019	N	M	39	14,2467086	-1,0547985	1051,19466	P	H
51	16,3214946	-1,6303456	321,846931	N	H	41	14,9950499	-1,1478854	1147,55041	P	M
53	14,5967834	-1,2668594	432,40477	N	M	45	14,0774092	-0,9771952	1536,05434	P	H
54	14,4448331	-1,403457	214,941491	N	M	46	14,6926345	-1,0627041	1518,59087	P	H
55	17,2535492	-1,8090673	304,556092	N	H	48	14,1296521	-1,1698575	479,773046	P	H
58	16,3431596	-1,4945291	551,860729	N	M	49	13,3843858	-0,8903473	1442,70349	P	H
59	14,9658742	-1,4409302	268,353065	N	H	52	15,5210681	-1,3192222	684,77082	P	H
61	15,3605317	-1,590966	202,95485	N	M	56	12,648013	-0,6095596	12296,3442	P	M
63	14,6600754	-1,33301	335,50959	N	H	57	14,5640845	-0,8653521	6957,99512	P	M

537

538

Supp. Table 1. AIC comparison of exponential Vs. potential model.

539

	nHCW (days)	eHCW (days)
Mean	265.1	38800.0
SD	108.0	186606.3
Median	229.2	1442.7

540

541

Supp. Table 2. Statistics of the estimations of days in which each group would reach an anti-

542

RBD IgG titer of 1000 UA/ml for the potential model in terms of mean, standard deviation (SD)

543

and median. Due to the nature of the model, the estimation of the potential model for long

544

periods of time develops an asymptotic behavior.